Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. - Wikidata - awgldk - TriplyDB

Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.

Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.

http://www.wikidata.org/entity/Q43901809

about

Therapeutic drug monitoring of antiretrovirals for people with HIV Neurotoxic effects of AZT on developing and adult neurogenesis AIDS diarrhea and antiretroviral drug concentrations: a matched-pair cohort study in Port au Prince, Haiti.Diarrhea and reduced levels of antiretroviral drugs: improvement with glutamine or alanyl-glutamine in a randomized controlled trial in northeast Brazil.A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial.Clinical evaluation of a dried blood spot assay for atazanavir 3'-Azido-3'-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria.Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents.Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.Therapeutic drug monitoring in human immunodeficiency virus/acquired immunodeficiency syndrome. Quo vadis?Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure.Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.Therapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects Gender: a possible determinant in dosing of dermatologic drugs--an overview.Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection.High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir.Pharmacologic consideration for the use of antiretroviral agents in the elderly.Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults.Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.Controlling the Evolution of Resistance Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.Dosing nucleoside reverse transcriptase inhibitors in adults receiving continuous veno-venous hemofiltration.Evaluation of nucleoside reverse transcriptase inhibitor dosing during continuous veno-venous hemofiltration.Special considerations concerning the use of antiretroviral drugs in children.Randomized exposure-controlled trials; impact of randomization and analysis strategies.

P2860

Q24239932-61B1FBC5-ACD1-44C9-B0BF-B9F1120C730D Q30414740-6A718EB5-7FD8-4912-87FB-F344624C1157 Q30426578-C967BC10-A3FD-42F4-BDDD-969B08FE59A1 Q30433860-A1F4390B-9E38-4D1F-A0D4-ACCA2E63F666 Q33559216-6E8678FF-91B9-43DC-8EB3-3A4897D4AB3D Q33681426-716D46E7-134B-414F-A977-16C6D70A98CE Q33821257-E376466C-65FA-4309-B24C-554B66D4C010 Q34039225-0F426FB0-41A2-4B54-80F2-845173416697 Q34114808-C6F0EA17-5A0A-4943-B4AA-F9179F6D4D9B Q34150893-226EE30B-D7CC-4A59-80CD-DD1CB2EA062E Q34695913-671D71CD-52BE-43B1-807D-C42CE9653634 Q34973688-E1972F76-362F-4C13-880E-1742EC380E1A Q35013781-E8D84C00-80A2-478E-A948-68F19F6D0287 Q35023687-78679B88-224C-4B15-AA84-F5871AA73F74 Q35058068-56E14723-C25E-449E-A317-5D9E4D648171 Q35082567-E9954E18-DE1A-44BB-82E2-62C0919CA508 Q35826795-AF058FA9-25C4-4EB7-8E26-0CCA010BA01D Q35898538-12CBFE96-90C9-424B-B331-441F1423E155 Q36036400-B74F3A1D-F037-413C-BA27-68BDCC2D3175 Q36376533-0DD05851-D34F-4294-8C0E-C90B22012CE7 Q36489794-9E0E009B-8073-4C88-A0F6-530FE138B847 Q36491897-F176F971-005A-4D56-BF55-CA96D0F430D7 Q36596188-F65105CF-7DCE-4EF2-9200-1ED206C4EB15 Q36667227-792945B1-3A7D-41B4-A350-1E09C6A752D9 Q36744874-9BE237BC-3E1B-4B30-84A2-444A323AADB4 Q36795898-8043D2E6-2387-4D21-A0EF-729ACA3C87B3 Q36870884-4597B789-18DF-41B0-9E12-EF06332E9BDC Q37277510-C7F1E9D4-EAE5-439C-A9E4-D184DB052A97 Q37298637-B9F4D016-A89A-4441-B0FB-9124A6570B0F Q37378110-9EA205EE-C34B-4C79-810D-DF508617146C Q37489345-4C0137AC-3B75-4A8B-A904-6AAC1703FB6F Q37598636-FCB1BAB1-C2A4-4BA2-8FAB-9BDF78A8E7B8 Q37692028-830BA70B-9614-4BA6-9A72-3A15CD511296 Q37835819-89851149-73AA-48FD-8D7C-FA24E5BEE9A4 Q37868426-B89E0190-10FA-4E46-93F3-BAA7E0594C78 Q38954109-C7BB9888-BE7B-4B34-AD8E-1CCD1DDE1E4A Q39037792-190BF38C-D15F-48A3-B683-5BFECA050B60 Q40435430-1A96F601-F236-4A21-AA76-F71364CD5010 Q40535139-9236D296-99F8-46A3-A61B-B20F6096BBC3 Q41121488-68F95618-5F2B-4595-B129-E210253B2055

P2860

Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.

http://www.wikidata.org/entity/Q43901809

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Concentration-controlled compa ...... ral therapy for HIV infection.

@en

Concentration-controlled compa ...... ral therapy for HIV infection.

@nl

type

label

Concentration-controlled compa ...... ral therapy for HIV infection.

@en

Concentration-controlled compa ...... ral therapy for HIV infection.

@nl

prefLabel

Concentration-controlled compa ...... ral therapy for HIV infection.

@en

Concentration-controlled compa ...... ral therapy for HIV infection.

@nl

P1433

Q43901809-BB8BF755-6798-4F0C-8D98-A8F29FBD47F2

P1476

Q43901809-79410FD2-F062-4287-8B9B-603E14313BD5

P2093

Q43901809-259224C7-01E5-443B-810F-79D42003590B

Q43901809-2A48755F-DD30-481B-B7B4-7ADB03B7C0A4

Q43901809-2B92E094-4661-4D72-967A-7DB20D8E457D

Q43901809-3029437B-585D-4923-83B0-52A2AD80A300

Q43901809-39134866-0D8B-4907-A739-7FB4C64C0B2F

Q43901809-A16CAF68-45A2-41F5-B988-768952C435AC

Q43901809-F4EBDE21-3317-4515-8E4A-295FFBB0AA5C

P304

Q43901809-F036CA5A-FBC0-4440-A933-4E05D4812966

P31

Q43901809-5E94A3DA-5F56-4CE0-BE4B-B43ECB6044BD

P356

Q43901809-2E3D1256-2D4F-493C-BE3C-D30D6157BEFA

P407

Q43901809-678FD64D-F233-40F7-91B4-99EBE384B232

P433

Q43901809-BA39B4D9-E298-45BB-8778-2AD0326D1093

P478

Q43901809-AFBB0A09-A09D-4C02-A6AD-77E5220AA836

P577

Q43901809-B7CE0627-FF04-4C11-B001-BB0AF1EF7413

P698

Q43901809-A53FD541-09A7-492B-BCF4-8742E91510F8

P356

00002030-200203080-00006

P1433

P1476

Concentration-controlled compa ...... ral therapy for HIV infection.

@en

P2093

Courtney V Fletcher

http://www.w3.org/2001/XMLSchema#string

Cynthia R Gross

http://www.w3.org/2001/XMLSchema#string

Keith Henry

http://www.w3.org/2001/XMLSchema#string

Peter L Anderson

http://www.w3.org/2001/XMLSchema#string

Richard C Brundage

http://www.w3.org/2001/XMLSchema#string

Thomas N Kakuda

http://www.w3.org/2001/XMLSchema#string

Timothy W Schacker

http://www.w3.org/2001/XMLSchema#string

P304

551-560

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/00002030-200203080-00006

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11872998

http://www.w3.org/2001/XMLSchema#string